JP2022541502A5 - - Google Patents

Info

Publication number
JP2022541502A5
JP2022541502A5 JP2022502832A JP2022502832A JP2022541502A5 JP 2022541502 A5 JP2022541502 A5 JP 2022541502A5 JP 2022502832 A JP2022502832 A JP 2022502832A JP 2022502832 A JP2022502832 A JP 2022502832A JP 2022541502 A5 JP2022541502 A5 JP 2022541502A5
Authority
JP
Japan
Prior art keywords
hla
cells
preparation
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502832A
Other languages
English (en)
Japanese (ja)
Other versions
JP7708737B2 (ja
JP2022541502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042768 external-priority patent/WO2021011936A2/en
Publication of JP2022541502A publication Critical patent/JP2022541502A/ja
Publication of JP2022541502A5 publication Critical patent/JP2022541502A5/ja
Application granted granted Critical
Publication of JP7708737B2 publication Critical patent/JP7708737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502832A 2019-07-18 2020-07-20 細胞の細胞型選択的免疫保護 Active JP7708737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875883P 2019-07-18 2019-07-18
US62/875,883 2019-07-18
PCT/US2020/042768 WO2021011936A2 (en) 2019-07-18 2020-07-20 Cell-type selective immunoprotection of cells

Publications (3)

Publication Number Publication Date
JP2022541502A JP2022541502A (ja) 2022-09-26
JP2022541502A5 true JP2022541502A5 (cg-RX-API-DMAC7.html) 2023-07-06
JP7708737B2 JP7708737B2 (ja) 2025-07-15

Family

ID=71995146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502832A Active JP7708737B2 (ja) 2019-07-18 2020-07-20 細胞の細胞型選択的免疫保護

Country Status (6)

Country Link
US (1) US20220267737A1 (cg-RX-API-DMAC7.html)
EP (1) EP3999627A2 (cg-RX-API-DMAC7.html)
JP (1) JP7708737B2 (cg-RX-API-DMAC7.html)
CN (1) CN114787358B (cg-RX-API-DMAC7.html)
CA (1) CA3144687A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021011936A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3766962B1 (en) 2013-02-06 2025-10-22 University of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
WO2023150553A1 (en) * 2022-02-01 2023-08-10 University Of Rochester Gpr17 promoter-based targeting and transduction of glial progenitor cells
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
US12303549B2 (en) 2018-06-21 2025-05-20 University Of Rochester Methods of treating or inhibiting onset of Huntington's disease
EP4125961A1 (en) 2020-03-25 2023-02-08 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
WO2024149906A1 (en) * 2023-01-13 2024-07-18 Laverock Therapeutics Limited Cell context-specific gene regulation using inhibitory rnas
WO2025222093A2 (en) * 2024-04-19 2025-10-23 Factor Bioscience Inc. Engineered cells and uses thereof
WO2025250531A1 (en) * 2024-05-28 2025-12-04 Thymmune Therapeutics, Inc. Hypoimmune engineering for universal ipsc-derived cells

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
WO2001053503A1 (en) 2000-01-18 2001-07-26 Cornell Research Foundation, Inc. Neural progenitor cells from hippocampal tissue and a method for isolating and purifying them
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
WO2003014320A2 (en) 2001-08-10 2003-02-20 Cornell Research Foundation, Inc. Telomerase immortalized human neutral stem cells and phenotypically-restricted progenitor cells
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
US20030223972A1 (en) 2002-02-15 2003-12-04 Goldman Steven A. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
US8642332B2 (en) 2003-03-07 2014-02-04 Cornell Research Foundation, Inc. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain
US8263406B2 (en) 2003-06-11 2012-09-11 Cornell Research Foundation, Inc. Enriched or purified population of motor neurons and its preparation from a population of embryonic stem cells
EP2182063A3 (en) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
CA2547474A1 (en) 2003-11-10 2005-05-26 Cornell Research Foundation, Inc. Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter
JP2010500029A (ja) 2006-08-11 2010-01-07 ダウ アグロサイエンシィズ エルエルシー ジンクフィンガーヌクレアーゼ媒介相同組換え
US8012678B2 (en) 2007-07-24 2011-09-06 Wisconsin Alumni Research Foundation Biomarkers for human papilloma virus-associated cancer
KR20100080068A (ko) 2008-12-31 2010-07-08 주식회사 툴젠 신규한 징크 핑거 뉴클레아제 및 이의 용도
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
WO2013074999A1 (en) 2011-11-16 2013-05-23 Sangamo Biosciences, Inc. Modified dna-binding proteins and uses thereof
EP3766962B1 (en) 2013-02-06 2025-10-22 University of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
EP3004339B1 (en) 2013-05-29 2021-07-07 Cellectis New compact scaffold of cas9 in the type ii crispr system
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
BR112015031639A2 (pt) * 2013-06-19 2019-09-03 Sigma Aldrich Co Llc integração alvo
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
CN106536721B (zh) 2014-08-06 2020-12-04 车医科学大学校产学协力团 核酸酶介导的编辑编码hla的基因所产生的免疫相容性细胞
EP3294342A4 (en) * 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells

Similar Documents

Publication Publication Date Title
JP7581183B2 (ja) ユニバーサルドナー細胞
US11434505B2 (en) Universal donor cells
US11433103B2 (en) Universal donor cells
JP2021106611A (ja) ヌクレアーゼ介在性遺伝子発現調節
JP2016513460A (ja) Hlaを修飾するための方法および組成物
JP2024532772A5 (cg-RX-API-DMAC7.html)
JP2022547505A5 (cg-RX-API-DMAC7.html)
JP2024503291A (ja) ユニバーサルドナー細胞
WO2017197141A2 (en) Targeted treatment of androgenic alopecia
CN117716026A (zh) 具有氧化应激抗性的间充质干细胞、其制备方法及用途
JP2025527629A (ja) 治療用細胞
Santore et al. Prenatal stem cell transplantation and gene therapy
EP4488364A1 (en) Low immunogenic stem cells, low immunogenic cells differentiated or derived from stem cells, and production method therefor
CN115803436A (zh) 免疫原性降低的新型移植细胞
WO2021172583A1 (ja) 遺伝子改変巨核球、改変血小板及びそれらの製造方法
KR20260032524A (ko) 저면역원성의 범용성 유도만능줄기세포
WO2024008979A1 (en) A sirp-alpha binding chimeric protein
WO2024133648A2 (en) Nk cell activating receptor ligand knockouts for use in cell therapy
Kaneko et al. Uphill Battle of CRISPR/Cas9: A Budding Technology in Need of Refinement